Authors: Jan Peter Yska Douwe H van der Meer Albert R Dreijer Willeke Eilander Jan A Apers Marloes Emous Erik R E Totté Bob Wilffert Eric N van Roon
Publish Date: 2015/11/03
Volume: 72, Issue: 2, Pages: 203-209
Abstract
Bariatric surgery can influence the prevalence and incidence of comorbidities as well as the pharmacokinetics of drugs This might lead to changes in the use of drugs This study aimed to assess the influence of bariatric surgery on the use of medication in patients before and after surgery focusing on type number of medications and daily dosageIn a retrospective and prospective observational study drug dispensing data from pharmacies of patients undergoing their first bariatric surgery between January 2008 and September 2011 was collected Dispensing data from 1 month before until 12 months after surgery was analyzed Drugs were classified according to the WHOATC classification system Dosages of drugs were compared using defined daily dose DDDAmong 450 patients 12 months after surgery the mean number of drugs per patient for antidiabetics drugs acting on the cardiovascular system antiinflammatory and antirheumatic drugs and drugs for obstructed airway diseases decreased by respectively 713 95 CI 572 to 854 345 95 CI 282 to 430 455 95 CI 133 to 726 and 331 95 CI 153 to 532 Patients used lower median DDD of oral antidiabetics betablocking agents and lipidmodifying drugsFor some major drug classes 12 months after bariatric surgery the use of drugs decreases in terms of mean number per patient A reduction in dose intensity was observed for oral antidiabetics betablocking agents and lipidmodifying drugs Dispensing data from pharmacies may provide detailed information on the use of medications by patients after bariatric surgeryResults from this study were presented in part in an oral presentation at the Jahrestagung 2014 DGPT Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie in April 2014 NaunynSchmiedeberg’s Archives of Pharmacology 2014 3 Suppl 1S223
Keywords: